|
|
孕期血清抗磷脂抗体水平变化及临床意义
|
Abstract:
目的：通过检测全孕期健康女性血清抗心磷脂(aCL)及抗β2糖蛋白1抗体(aβ2GPI)水平，建立郑州市健康孕期抗体的参考区间，分析孕期抗体变化的特点及临床意义。方法：纳入2023.5~2023.10于郑大二附院建档围保的134名健康孕期女性检测aCL和aβ2GPI-IgA/IgM/IgG血清水平，使用非参数法计算各百分位值，同期纳入78例孕前检测抗磷脂抗体阳性的孕妇，收集其孕后抗体水平及治疗用药和妊娠结局。结果：1) 正常妊娠妇女剔除离群值后，aCL和aβ2GPI-IgA/IgM/IgG的P99值分别为：4.78 RU/mL、29.18 RU/mL、3.33 RU/mL、4.88 RU/mL、11.44 RU/mL、<2 RU/mL，与243例非孕期健康育龄期女性相比，孕期健康育龄期女性aCL-IgM和aβ2GPI-IgM水平显著降低(P < 0.05)，不同孕期抗体水平间无统计学差异。2) 孕前抗体阳性孕妇，孕后各型抗体水平随孕周增加逐渐降低，孕前、孕后抗体水平间比较具有显著的统计学差异(P < 0.01)；26例恢复正常孕期范围后停用免疫抑制剂，停药与未停药者20周后持续妊娠率及活产率均为100%；以每项正常抗磷脂抗体95%截断值上限为1，计算孕前阳性的抗磷脂抗体的最大倍数，ROC计算最大倍数的最佳截断值为2.725，AUC = 0.91；Logistic回归分析显示最大倍数、年龄、不良孕产次均为不良妊娠结局的独立影响因素(P < 0.01)。结论：健康孕期女性的aCL-IgM和aβ2GPI-IgM水平显著降低，抗体阳性者孕后其水平显著降低，孕前APLs升高2.725倍与不良妊娠结局相关。
Objective: By detecting serum levels of anticardiolipin (aCL) and anti-β-2-glycoprotein I antibody (aβ2GPI) in healthy women throughout pregnancy, establish a reference interval for healthy pregnancy antibodies in Zhengzhou city, and analyze the characteristics and clinical significance of changes in pregnancy antibodies. Method: Serum levels of aCL and aβ2GPI-IgA/IgM/IgG were tested in 134 healthy pregnant women who were included in the perioperative period of the Second Affiliated Hospital of Zhengzhou University from March 3, 2023 to October 2023. Non parametric methods were used to calculate the percentile values. During the same period, 78 pregnant women who tested positive for antiphospholipid antibodies before pregnancy were included, and their post pregnancy antibody levels, treatment medication, and pregnancy outcomes were collected. Result: 1) After excluding outliers in normal pregnant women, The P99 of aCL and aβ2GPI-IgA were 4.78 RU/mL, 29.18 RU/mL, 3.33 RU/mL, 4.88 RU/mL, 11.44 RU/mL, and <2 RU/mL, respectively. Compared with 243 non pregnant healthy reproductive age women, aCL-IgM and aβ2GPI-IgM significantly decreased (P < 0.05), and there was no statistically significant difference in antibody levels between different pregnancy periods. 2) Pregnant women with positive antibodies before pregnancy have gradually decreased levels of various types of antibodies with increasing gestational age. There is a significant statistical difference in antibody levels between pre pregnancy and post pregnancy (P < 0.01); after returning to normal pregnancy range, 26 cases stopped using immunosuppressive agents. The sustained pregnancy rate and live birth rate after 20 weeks were 100% for those who stopped and those who did not; the upper limit
| [1] | 孙莹, 杜惠兰, 李蓉, 等. 复发性流产中西医结合诊疗指南[J]. 中国中药杂志, 2024, 49(9): 2544-2556. https://doi.org/10.19540/j.cnki.cjcmm.20240130.501 |
| [2] | 产科抗磷脂综合征诊断与处理专家共识[J]. 中华围产医学杂志, 2020, 23(8): 517-522. |
| [3] | Miyakis, S., Lockshin, M.D., Atsumi, T., et al. (2006) International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome (APS). Journal of Thrombosis and Haemostasis, 4, 295-306. https://doi.org/10.1111/j.1538-7836.2006.01753.x |
| [4] | Tektonidou, M.G., Andreoli, L., Limper, M., et al. (2019) EULAR Recommendations for the Management of Antiphospholipid Syndrome in Adults. Annals of the Rheumatic Diseases, 78, 1296-1304. https://doi.org/10.1136/annrheumdis-2019-215213 |
| [5] | Elbagir, S., Mohammed, N.A., Kaihola, H., et al. (2020) Elevated IgA Antiphospholipid Antibodies in Healthy Pregnant Women in Sudan But Not Sweden, without Corresponding Increase in IgA Anti-β2 Glycoprotein I Domain 1 Antibodies. Lupus, 29, 463-473. https://doi.org/10.1177/0961203320908949 |
| [6] | Yelnik, C.M., Porter, T.F., Branch, D.W., et al. (2016) Brief Report: Changes in Antiphospholipid Antibody Titers during Pregnancy: Effects on Pregnancy Outcomes. Arthritis & Rheumatology, 68, 1964-1969. https://doi.org/10.1002/art.39668 |
| [7] | 周慧如, 周玉侠, 周凤荣, 等. 化学发光免疫分析法检测正常孕妇抗磷脂抗体水平及在不同孕期的比较[J]. 中华围产医学杂志, 2022, 25(11): 823-828. |
| [8] | 李诗雅, 邵文嘉, 冀恒涛, 等. 郑州地区健康育龄女性抗磷脂抗体参考区间的建立[J]. 河南医学研究, 2023, 32(12): 2130-2134. |
| [9] | Viall, C.A. and Chamley, L.W. (2015) Histopathology in the Placentae of Women with Antiphospholipid Antibodies: A Systematic Review of the Literature. Autoimmunity Reviews, 14, 446-471. https://doi.org/10.1016/j.autrev.2015.01.008 |
| [10] | Lynch, A.M., Rutledge, J.H., Stephens, J.K., et al. (1995) Longitudinal Measurement of Anticardiolipin Antibodies during Normal Pregnancy: A Prospective Study. Lupus, 4, 365-369. https://doi.org/10.1177/096120339500400506 |
| [11] | Topping, J., Quenby, S., Farquharson, R., et al. (1999) Marked Variation in Antiphospholipid Antibodies during Pregnancy: Relationships to Pregnancy Outcome. Human Reproduction, 14, 224-228. https://doi.org/10.1093/humrep/14.1.224 |
| [12] | Alazar-Páramo, M., Jara, L.J., Ramos, A., et al. (2002) Longitudinal Study of Antinuclear and Anticardiolipin Antibodies in Pregnant Women with Systemic Lupus Erythematosus and Antiphospholipid Syndrome. Rheumatology International, 22, 142-147. https://doi.org/10.1007/s00296-002-0207-x |
| [13] | Garcia, D. and Erkan, D. (2018) Diagnosis and Management of the Antiphospholipid Syndrome. The New England Journal of Medicine homepage, 378, 2010-2021. https://doi.org/10.1056/NEJMra1705454 |
| [14] | 郑晓娟, 邓晓莉, 刘湘源. 54例抗磷脂综合征患者的妊娠结局[J]. 北京大学学报(医学版), 2014, 46(2): 323-328. |
| [15] | 施君, 赵爱民. 妊娠合并抗磷脂综合征的诊治[J]. 中国实用妇科与产科杂志, 2016, 32(10): 948-952. |
| [16] | 刘平, 樊尚荣. 产科抗磷脂综合征的诊断和治疗[J]. 中华产科急救电子杂志, 2019, 8(2): 87-92. |
| [17] | 宋钰, 王海燕. 复发性流产合并抗磷脂抗体综合征诊疗进展[J]. 中国优生与遗传杂志, 2016, 24(5): 9-13. https://doi.org/10.13404/j.cnki.cjbhh.2016.05.004 |
| [18] | 王丽萍, 郭少华, 王春燕, 等. 小剂量丙种球蛋白治疗狼疮妊娠合并抗磷脂综合征患者的疗效观察[J]. 临床荟萃, 2019, 34(8): 724-729. |
